Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completion of the GWEP1521 Blinded Phase

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GWP42003-P (Type: EXPERIMENTAL): 100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.

Based on this trial design, predict the completion outcome and termination type (if applicable).